| 产品名称： | 1D4 |
|---|---|
| 商品货号： | TS212991 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The supernatant may have to be concentrated for use. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The original deposit of this cell line was contaminated with microorganisms. The line was treated with antibiotics and is now cured of the contamination. Animals were immunized with purified HSV-1 nucleocapsids. Spleen cells were fused with P3-NSI/1-Ag4-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against nucleocapsid (p40) of herpes simplex virus type 1 (HSV-1) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against nucleocapsid (p40) of herpes simplex virus type 1 (HSV-1) |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/c mice |
| Comments： | The original deposit of this cell line was contaminated with microorganisms. The line was treated with antibiotics and is now cured of the contamination. Animals were immunized with purified HSV-1 nucleocapsids. Spleen cells were fused with P3-NSI/1-Ag4-1 myeloma cells. The antibody precipitates p40 and p45 of HSV-1 but not HSV-2. The supernatant may have to be concentrated for use. |
| Complete Growth Medium： | Culture Medium: RPMI 1640 medium with 1 mM sodium pyruvate, 85%; fetal bovine serum, 15%. |
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium, 70%; fetal bovine serum, 20%; DMSO, 10% |
| Isotype： | IgG1 |
| Name of Depositor： | The United States of America |
| U.S. Patent Number： | |
| References： | Zweig M, et al. Production of monoclonal antibodies against nucleocapsid proteins of Herpes simplex Virus types 1 and 2. J. Virol. 32: 676-678, 1979. PubMed: 91687 Zweig M, et al. Test methods employing monoclonal antibodies against Herpes simplex virus types 1 and 2 nucleocapsids proteins. US Patent 4,430,437 dated Feb 7 1984 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 1D4 |
|---|---|
| 商品货号： | TS212991 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The supernatant may have to be concentrated for use. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The original deposit of this cell line was contaminated with microorganisms. The line was treated with antibiotics and is now cured of the contamination. Animals were immunized with purified HSV-1 nucleocapsids. Spleen cells were fused with P3-NSI/1-Ag4-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against nucleocapsid (p40) of herpes simplex virus type 1 (HSV-1) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against nucleocapsid (p40) of herpes simplex virus type 1 (HSV-1) |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/c mice |
| Comments： | The original deposit of this cell line was contaminated with microorganisms. The line was treated with antibiotics and is now cured of the contamination. Animals were immunized with purified HSV-1 nucleocapsids. Spleen cells were fused with P3-NSI/1-Ag4-1 myeloma cells. The antibody precipitates p40 and p45 of HSV-1 but not HSV-2. The supernatant may have to be concentrated for use. |
| Complete Growth Medium： | Culture Medium: RPMI 1640 medium with 1 mM sodium pyruvate, 85%; fetal bovine serum, 15%. |
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium, 70%; fetal bovine serum, 20%; DMSO, 10% |
| Isotype： | IgG1 |
| Name of Depositor： | The United States of America |
| U.S. Patent Number： | |
| References： | Zweig M, et al. Production of monoclonal antibodies against nucleocapsid proteins of Herpes simplex Virus types 1 and 2. J. Virol. 32: 676-678, 1979. PubMed: 91687 Zweig M, et al. Test methods employing monoclonal antibodies against Herpes simplex virus types 1 and 2 nucleocapsids proteins. US Patent 4,430,437 dated Feb 7 1984 |
